Bayer Outlines Asundexian Phase III Plan, Hoping To Prove Safety Benefit Over Eliquis

 
• By Jessica Merrill
Risk Sign
Bayer is looking to develop a oral anticoagulant with fewer bleeding risks • Source: Shutterstock

More from Blood and Clotting

More from Therapeutic Category